These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

289 related items for PubMed ID: 17140367

  • 21. Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks.
    Roukos DH, Ziogas DE, Katsios C.
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1187-95. PubMed ID: 20735306
    [Abstract] [Full Text] [Related]

  • 22. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 23. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.
    Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA.
    Cancer; 2009 Nov 01; 115(21):4917-23. PubMed ID: 19691094
    [Abstract] [Full Text] [Related]

  • 24. Molecular predictors of local tumor control in early-stage breast cancer.
    Miyamoto DT, Harris JR.
    Semin Radiat Oncol; 2011 Jan 01; 21(1):35-42. PubMed ID: 21134652
    [Abstract] [Full Text] [Related]

  • 25. New molecular classifications of breast cancer.
    Cianfrocca M, Gradishar W.
    CA Cancer J Clin; 2009 Jan 01; 59(5):303-13. PubMed ID: 19729680
    [Abstract] [Full Text] [Related]

  • 26. Pharmacogenomics in breast cancer: current trends and future directions.
    Wajapeyee N, Somasundaram K.
    Curr Opin Mol Ther; 2004 Jun 01; 6(3):296-301. PubMed ID: 15264432
    [Abstract] [Full Text] [Related]

  • 27. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.
    Breast Cancer Res Treat; 2009 Jul 01; 116(1):131-43. PubMed ID: 18668363
    [Abstract] [Full Text] [Related]

  • 28. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
    Lyman GH, Cosler LE, Kuderer NM, Hornberger J.
    Cancer; 2007 Mar 15; 109(6):1011-8. PubMed ID: 17311307
    [Abstract] [Full Text] [Related]

  • 29. [Histopathologic diagnosis of luminal and basal type breast cancer].
    Sarcević B.
    Acta Med Croatica; 2008 Oct 15; 62(4):427-30. PubMed ID: 19205420
    [Abstract] [Full Text] [Related]

  • 30. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study.
    Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, Klein B, Geffen DB, Kaufman B.
    Cancer; 2008 Feb 15; 112(4):731-6. PubMed ID: 18076012
    [Abstract] [Full Text] [Related]

  • 31. [Molecular portrait of breast cancer with sub-classification of breast tumor].
    Siegelmann-Danieli N, Stein ME, Wallach N.
    Harefuah; 2007 Jan 15; 146(1):48-52, 77-8. PubMed ID: 17294849
    [Abstract] [Full Text] [Related]

  • 32. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT, Byrnes K, Li BD, Turnage RH, Abreo F, Mathis JM, Chu QD.
    J Surg Res; 2007 Jul 15; 141(1):53-9. PubMed ID: 17574038
    [Abstract] [Full Text] [Related]

  • 33. Prediction of benefit from adjuvant treatment in patients with breast cancer.
    Eng-Wong J, Isaacs C.
    Clin Breast Cancer; 2010 Jul 15; 10 Suppl 1():E32-7. PubMed ID: 20587405
    [Abstract] [Full Text] [Related]

  • 34. Genomic subtypes in choosing adjuvant therapy for breast cancer.
    Zelnak AB, O'Regan RM.
    Oncology (Williston Park); 2013 Mar 15; 27(3):204-10. PubMed ID: 23687790
    [Abstract] [Full Text] [Related]

  • 35. Challenges in projecting clustering results across gene expression-profiling datasets.
    Lusa L, McShane LM, Reid JF, De Cecco L, Ambrogi F, Biganzoli E, Gariboldi M, Pierotti MA.
    J Natl Cancer Inst; 2007 Nov 21; 99(22):1715-23. PubMed ID: 18000217
    [Abstract] [Full Text] [Related]

  • 36. Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm.
    Rayhanabad JA, Difronzo LA, Haigh PI, Romero L.
    Am Surg; 2008 Oct 21; 74(10):887-90. PubMed ID: 18942607
    [Abstract] [Full Text] [Related]

  • 37. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
    Brenton JD, Carey LA, Ahmed AA, Caldas C.
    J Clin Oncol; 2005 Oct 10; 23(29):7350-60. PubMed ID: 16145060
    [Abstract] [Full Text] [Related]

  • 38. BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.
    D'Alfonso TM, van Laar RK, Vahdat LT, Hussain W, Flinchum R, Brown N, John LS, Shin SJ.
    Breast Cancer Res Treat; 2013 Jun 10; 139(3):705-15. PubMed ID: 23774991
    [Abstract] [Full Text] [Related]

  • 39. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
    Melchor L, Honrado E, García MJ, Alvarez S, Palacios J, Osorio A, Nathanson KL, Benítez J.
    Oncogene; 2008 May 15; 27(22):3165-75. PubMed ID: 18071313
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.